Amgen (AMGN) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Amgen (AMGN) to $330 from $328 and keeps an Equal Weight rating on the ...

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Amgen (AMGN – Research Report) today and set a price target of $330.00. The ...

with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Amgen is currently a Zacks Rank ...

The Dow Jones Industrial Average is declining Wednesday morning with shares of Amgen and Merck seeing the biggest losses for the price-weighted average. Shares of Amgen and Merck have contributed to ...

This multi-factor model seeks low volatility stocks that also have strong momentum and high net payout yields. AMGEN INC (AMGN) is a large-cap growth stock in the Biotechnology & Drugs industry.

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Amgen wasn’t one of them. The 10 stocks that made the cut ...

with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Amgen is currently a Zacks Rank #3 (Hold).

Amgen's sales growth is safe and should improve ... Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this. On rare occasions, our expert team ...

This multi-factor model seeks low volatility stocks that also have strong momentum and high net payout yields. AMGEN INC (AMGN) is a large-cap growth stock in the Biotechnology & Drugs industry.

Deep-pocketed investors have adopted a bearish approach towards Amgen (NASDAQ:AMGN), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.